PTPN22 and cancer: The challenges faced by adoptively transferred T cells in eliminating tumors is illustrated in Figure 5 and below we discuss studies that have targeted four phosphatases, PTPN2, PTPN22, SHP-1 and SHP-2 as a strategy of overcoming these hurdles and improving ACT in several cancer models (Table 3).